{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.14","upperLimit":"1.04","value":"0.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Testosterone"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.32","upperLimit":"1.37","value":"0.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Estradiol"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"1.57","value":"1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Prolactin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.59","upperLimit":"1.32","value":"0.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"LH Serum"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"1.65","value":"1.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Follicle Stimulating Hormone"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.68","upperLimit":"2.86","value":"1.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Free Testosterone"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.11","upperLimit":"0.46","value":"0.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Sex Hormone Binding Globulin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"1.34","value":"0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Dihydroepiandrosterone Sulfate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Geometric mean of ratio (Cycle 12 Day 1/Baseline) of hypogonadism parameters (total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin) levels in males was analyzed. Data for this outcome measure was planned to be collected for combined RP2D Cohort only, excluding arms of low and high dose escalation cohorts. 95% CI should be interpreted with cautions due to the limited sample size at this time point.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.","id":"OG000","title":"RP2D Cohort: Crizotinib 250 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Hypogonadism test evaluable population: Male participants who had completed screening, had received at least 1 dose of crizotinib on Cycle 1 Day 1, had at least 1 post baseline visit data for at least total testosterone, free testosterone, SHBG and included male participants of MET amplification and enriched other Cohort following approval of protocol amendment number 21. \"N\" =participants evaluable for this OM and 'number analyzed' =participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 12 Day 1","title":"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1","type":"PRIMARY","unitOfMeasure":"Ratio"}